HCA (HCA Healthcare, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by HCA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-28 | Michael R McAlevey | EVP & Chief Legal & Admin Off. | J | — | — |
| 2026-05-11 | Mike A Marks | EVP and CFO | G | — | — |
| 2026-04-30 | JOHN CHIDSEY | Director | A | — | — |
| 2026-04-30 | NANCY ANN DEPARLE | Director | A | — | — |
| 2026-04-30 | Hugh F Johnston | Director | A | — | — |
| 2026-04-30 | MICHAEL W MICHELSON | Director | A | — | — |
| 2026-04-30 | Wayne Joseph Riley | Director | A | — | — |
| 2026-04-30 | Andrea B Smith | Director | A | — | — |
| 2026-04-30 | THOMAS F FRIST III | Director | A | — | — |
| 2026-04-30 | William R Frist | Director | A | — | — |
| 2026-02-18 | Michael R McAlevey | EVP & Chief Legal & Admin Off. | MIXED | — | — |
| 2026-02-12 | Jennifer Berres | SVP & Chief Human Res. Officer | MIXED | — | — |
| 2026-02-12 | Michael S. Cuffe | EVP and Chief Clinical Officer | MIXED | — | — |
| 2026-02-12 | Jon M Foster | EVP and COO | MIXED | — | — |
| 2026-02-12 | SAMUEL N HAZEN | CEO | MIXED | — | — |
| 2026-02-12 | Mike A Marks | EVP and CFO | MIXED | — | — |
| 2026-02-12 | Michael R McAlevey | EVP & Chief Legal & Admin Off. | MIXED | — | — |
| 2026-02-12 | Erica Rossitto | SVP & Chief Nurse Executive | MIXED | — | — |
| 2026-02-12 | Christopher F. Wyatt | SVP & Controller | MIXED | — | — |
| 2026-02-10 | Frisco Holding II | 10%+ Owner | J | — | — |
| 2026-02-10 | HERCULES HOLDING II | 10%+ Owner | J | — | — |
| 2026-02-10 | Patricia F Elcan | 10%+ Owner | J | — | — |
| 2026-02-10 | THOMAS F FRIST III | Director | J | — | — |
| 2026-02-10 | William R Frist | Director | J | — | — |
| 2026-02-10 | THOMAS F FRIST JR | 10%+ Owner | J | — | — |
| 2026-02-09 | Jon M Foster | EVP and COO | MIXED | — | — |
| 2026-02-09 | Christopher F. Wyatt | SVP & Controller | MIXED | — | — |
| 2026-02-05 | Michael S. Cuffe | EVP and Chief Clinical Officer | MIXED | — | — |
| 2026-02-05 | SAMUEL N HAZEN | CEO | MIXED | — | — |
| 2026-02-02 | Jennifer Berres | SVP & Chief Human Res. Officer | A | — | — |
| 2026-02-02 | Michael S. Cuffe | EVP and Chief Clinical Officer | A | — | — |
| 2026-02-02 | Jon M Foster | EVP and COO | A | — | — |
| 2026-02-02 | SAMUEL N HAZEN | CEO | MIXED | — | — |
| 2026-02-02 | Mike A Marks | EVP and CFO | A | — | — |
| 2026-02-02 | Michael R McAlevey | EVP & Chief Legal & Admin Off. | A | — | — |
| 2026-02-02 | Christopher F. Wyatt | SVP & Controller | A | — | — |
| 2025-11-18 | SAMUEL N HAZEN | CEO | G | — | — |
| 2025-11-05 | Mike A Marks | EVP and CFO | G | — | — |
| 2025-11-05 | Michael R McAlevey | EVP & Chief Legal & Admin Off. | MIXED | — | — |
| 2025-11-04 | SAMUEL N HAZEN | CEO | MIXED | — | — |
| 2025-09-08 | Michael S. Cuffe | EVP and Chief Clinical Officer | MIXED | — | — |
| 2025-07-31 | JOHN CHIDSEY | Director | A | — | — |
| 2025-05-15 | Jon M Foster | EVP and COO | MIXED | — | — |
| 2025-05-15 | SAMUEL N HAZEN | CEO | G | — | — |
| 2025-05-08 | Mike A Marks | EVP and CFO | MIXED | — | — |
| 2025-05-01 | Robert J Dennis | Director | A | — | — |
| 2025-05-01 | NANCY ANN DEPARLE | Director | A | — | — |
| 2025-05-01 | Hugh F Johnston | Director | A | — | — |
| 2025-05-01 | MICHAEL W MICHELSON | Director | A | — | — |
| 2025-05-01 | Wayne Joseph Riley | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 50,331,374 | — |
| — | 10%+ Owner | 49,912,261 | — |
| — | 10%+ Owner | 32,323,941 | — |
| — | 10%+ Owner | 32,282,889 | — |
| — | Director | 30,003,156 | — |
| — | 10%+ Owner | 30,003,156 | — |
| — | Director | 30,003,156 | — |
| — | 10%+ Owner | 27,440,990 | — |
| — | Director | 7,612,921 | — |
| — | 10%+ Owner | 5,070,248 | — |
| — | 10%+ Owner | 5,070,248 | — |
| — | 10%+ Owner | 2,652,364 | — |
| — | 10%+ Owner | 2,337,018 | — |
| — | 10%+ Owner | 2,050,195 | — |
| — | Chairman | 1,081,823 | — |
| — | 10%+ Owner | 750,831 | — |
| — | 10%+ Owner | 750,831 | — |
| — | Chairman | 718,952 | — |
| — | 10%+ Owner | 687,808 | — |
| — | Group President | 516,429 | — |
| — | 10%+ Owner | 482,824 | — |
| — | 10%+ Owner | 478,955 | — |
| — | 10%+ Owner | 422,227 | — |
| — | SVP and CIO | 330,148 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HCA quote page; the site-wide leaderboard is on the insider transactions hub.